Conference being held October 6-8, 2025, in Phoenix, Arizona

MONTREAL, September 23, 2025 – ExCellThera Inc. (ExCellThera), a world leader in enhanced blood stem cell expansion and therapies, announced today that its CEO, David Millette, will present at the annual Cell & Gene Meeting on the Mesa conference to be held on October 6-8, 2025, at the Arizona Biltmore in Phoenix, Arizona.

The presentation will provide an overview of the company, including:

  • Zemcelpro® (UM171 Cell Therapy) which recently received, through wholly owned subsidiary Cordex Biologics, conditional marketing authorization by the European Commission for the treatment of adults with haematological malignancies requiring an allogeneic stem cell transplant without access to suitable donor cells
  • Strategic partnership opportunities to support and accelerate the commercialization of Zemcelpro® in Europe and other international markets
  • The use and availability of small molecule UM171, with its first-in-class mechanism of action for ex vivo expansion and metabolic fitness, in other cell and gene therapy applications
Event: ExCellThera Company Presentation
Date: Tuesday, October 7, 2025
Time: 3:15 PM MT (6:15 PM ET)
Location: Ballroom F, Arizona Biltmore Hotel, Phoenix, Arizona and livestream

Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures.

About Zemcelpro®
Zemcelpro®, also known as UM171 Cell Therapy, is a novel personalized cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit.

Conditional marketing authorization has recently been granted by the European Commission to Zemcelpro® for the treatment of adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning for whom no other type of suitable donor cells is available.

The timing of Zemcelpro® availability in individual countries will depend on several factors, including the completion of national reimbursement procedures. In the meantime, Cordex Biologics is working closely with national health authorities to enable early access for eligible patients ahead of the reimbursement process, and is engaging with leading stem cell transplantation centers to establish a network of treatment centers for the future administration of Zemcelpro®. Cordex Biologics is also actively seeking strategic partnerships to support and accelerate the commercialization of Zemcelpro in Europe and other international markets.

For full details on the Warnings and Precautions for Use and Adverse Reactions (including appropriate management), please refer to the EU Summary of Product Characteristics (SmPC) of Zemcelpro®.

Zemcelpro®, developed by Cordex Biologics, a wholly owned subsidiary of ExCellThera, has been evaluated in 120 patients with haematologic malignancies in clinical trials in the United States, Europe and Canada. Zemcelpro® has received orphan drug designation and regenerative medicine advanced therapy (RMAT) designations from the FDA as well as orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification and priority medicines (PRIME) designation from the EMA.

Zemcelpro® has been tested in Phase 2 trials in patients with high and very high-risk acute leukemias and myelodysplasias who have limited treatment options with low survival outcomes and high incidence of relapse under the current standard of care, including patients with patients with TP53 mutations or other genetic abnormalities, patients requiring a second transplant, and patients with refractory or active disease. A pivotal Phase 3 trial in this patient population will be initiated as soon as possible.

The use of Zemcelpro® in other patient populations, including pediatric patients and patients with non-malignant haematological diseases, is also being investigated.

The product safety and efficacy have not yet been established by other regulatory agencies, such as the FDA, the MHRA and Health Canada.

About ExCellThera and UM171 Technology
ExCellThera is a world leader in enhanced blood stem cell therapies. ExCellThera’s proprietary EnhanceTM platform for cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the EnhanceTM platform, including the proprietary molecule UM171 which has a first-in-class mechanism of action for ex vivo expansion and metabolic fitness of HSCs. For additional information, visit excellthera.com, and follow us on LinkedIn.

Zemcelpro® is a registered trademark of ExCellThera or its related companies.